Ibuzatrelvir

Small molecule

Also known as PF-07817883

Phase 3underway

Evidence outlook · registrational

COVID-19: registrational readout pending

Its supporting mid-stage studies have completed. Registrational readout expected around 2027-09-28.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
COVID-19
NCT07013474 · Pfizer
2025-07-14 – 2028-02-05 · COVID-19 Infection
What this study did
Phase 2 (1)
COVID-19
NCT05799495 · Pfizer
2023-05-23 – 2023-10-11 · SARS-CoV-2 Infection
What this study did
Phase 1 (9)
COVID-19
NCT07552779 · Pfizer
2026-04-13 – 2026-06-29 · Coronavirus Disease 2019, Coronavirus Disease 2019 (COVID-19), COVID-19 (Coronavirus Disease 2019), Upper Respiratory Tract Infections, Respiratory Tract Infection, Respiratory Tract Diseases, COVID-19, COVID-19 Infection, COVID-19 SARS-CoV-2 Infection, Pneumonia, Lung Diseases
What this study did
NCT06586216 · Pfizer
2024-09-10 – 2025-02-13 · COVID-19
What this study did
NCT05884554 · Pfizer
2023-06-15 – 2024-06-27 · COVID-19
What this study did
Other / comorbidity
NCT07235137 · Pfizer
2025-10-16 – 2025-11-21 · Healthy Participant
What this study did
NCT06122194 · Pfizer
2023-11-23 – 2024-01-12 · Healthy
What this study did
NCT05580003 · Pfizer
2022-10-17 – 2023-09-15 · Healthy
What this study did
NCT05822440 · Pfizer
2023-04-13 – 2023-07-10 · Healthy
What this study did

Competitive landscape

This drug's own stage for COVID-19: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ibuzatrelvir: this drugPhase 3Small moleculeSARS-CoV-2 3CL proteasenot yet gradedNo reviewed efficacy summary in this indication
Baricitinib (Olumiant)ApprovedSmall moleculeJAK, JAK1/2not yet gradedNo reviewed efficacy summary in this indication
BAT1806 (Tofidence)ApprovedMonoclonal antibodyIL-6 receptornot yet gradedNo reviewed efficacy summary in this indication
CT-P47 (tocilizumab) (Avtozma)ApprovedMonoclonal antibodyIL-6R antagonistnot yet gradedNo reviewed efficacy summary in this indication
Elasomeran (Spikevax)ApprovedVaccineSARS-CoV-2 spike proteinReliable signalNo reviewed efficacy summary in this indication
Tocilizumab (Actemra / RoActemra)ApprovedMonoclonal antibodyIL-6 receptorPartial signal
NCT04409262: Time to Hospital Discharge or "Ready for Discharge" up to Day 28 (Up to Day 28): Remdesivir + Placebo (RDV+Placebo) - mITT Population 14 days (95% CI 11 to 16) | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population 14 days (95% CI 12 to 15) missed
NCT04372186: Cumulative Proportion of Participants Who Died or Required Mechanical Ventilation by Day 28 (Up to Day 28): Tocilizumab 12.04 Percentage of Participants (95% CI 8.52 to 16.86) | Placebo 19.26 Percentage of Participants (95% CI 13.34 to 27.36)
Azvudine (FNC)Phase 3Small moleculeHIV reverse transcriptasenot yet gradedNo reviewed efficacy summary in this indication
Levilimab (Ilsira)Phase 3Monoclonal antibodyIL-6 receptornot yet gradedNo reviewed efficacy summary in this indication
MasitinibPhase 2Small moleculeKIT (c-Kit), also PDGFR and Lyn/Fyn kinasesnot yet gradedNo reviewed efficacy summary in this indication
GSK4396687
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ibuzatrelvir to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
September 2027 (1)
Phase 3COVID-19Recruiting
Est. primary completion 2027-09-28 · NCT07013474 · CT.gov ↗
What to watch
October 2027 (1)
Phase 3COVID-19Recruiting
Est. primary completion 2027-10-01 · NCT06679140 · CT.gov ↗
What to watch

See the full readout calendar ↗